CD274 and pancreatic neoplasm: Moreover, it needs to be tested whether losartan can potentiate the response to PD-(L)1 blockade in other cancers associated with peritumoral fibrosis and desmoplasia, such as pancreatic cancer and intrahepatic cholangiocarcinoma, which so far have been refractory to ICI.